ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2024, Vol. 16 ›› Issue (5): 431-435.doi: 10.3969/j.issn.1674-3865.2024.05.015

• 临床研究 • 上一篇    下一篇

小儿咳喘灵口服液(浓缩型)治疗儿童肺炎支原体肺炎的临床疗效观察

瞿圣岳, 穆婧雯, 杨建树, 赵航宇, 张秀英, 王雪峰   

  1. 110847 沈阳，辽宁中医药大学第一临床学院2022级中医儿科学研究生（瞿圣岳，穆婧雯，杨建树，赵航宇）；110032 沈阳，辽宁中医药大学附属医院儿科（张秀英，王雪峰）

  • 收稿日期:2024-10-11 修回日期:2024-10-13 出版日期:2024-10-25 上线日期:2024-10-25
  • 通讯作者: 王雪峰,E-mail：lnzywxf@163.com
  • 基金资助:
    基于重点研究室研究领域的中医药多学科研究能力提升项目(2022-304)；国家中医药传承创新中心重点病种项目(2023-247)

Clinical efficacy observation of Xiaoer Kechuanling oral solution (concentrated) in the treatment of Mycoplasma pneumoniae pneumonia in children

QU Shengyue1,MU Jingwen1,YANG Jianshu1,ZHAO Hangyu1,ZHANG Xiuying2,WANG Xuefeng2   

  1. 1Liaoning University of Traditional Chinese Medicine，Shenyang 110847,China；2Affiliated Hospital of Liaoning University of Traditional Chinese Medicine，Shenyang 110032,China
  • Received:2024-10-11 Revised:2024-10-13 Published:2024-10-25 Online:2024-10-25
  • Contact: WANG Xuefeng,E-mail：lnzywxf@163.com

PDF (PC)

109

摘要： 目的：探讨小儿肺炎支原体肺炎应用小儿咳喘灵口服液(浓缩型)的临床疗效及炎性因子水平的变化情况。方法：选取辽宁中医药大学附属医院儿科就诊的肺炎支原体肺炎患儿，计划纳入110例，随机分为观察组和对照组各55例。对照组用西医基础治疗，观察组在对照组治疗基础上联合小儿咳喘灵口服液(浓缩型)治疗。治疗7 d后比较两组患儿的临床疗效、症状持续时间、肺部啰音持续时间，炎性因子水平、不良反应发生情况。结果：观察组总有效率为94.55%(52/55),高于对照组81.82%(45/55),差异有统计学意义(P<0.05)。观察组发热、咳嗽、咯痰、肺部啰音持续时间较对照组均明显缩短，差异有统计学意义(P<0.05)。两组治疗方案对肺炎支原体肺炎患儿TNF-α水平改善的差异无统计学意义(P>0.05)。两组治疗方案对肺炎支原体肺炎患儿IL-6水平改善的差异有统计学意义(P<0.05)。治疗期间两组不良反应发生率比较差异无统计学意义(P>0.05)。结论：在西医治疗基础上，应用小儿咳喘灵口服液(浓缩型)治疗儿童肺炎支原体肺炎可有效提高临床疗效，缩短发热、咳嗽、咯痰、肺部啰音持续时间，抑制炎症反应，且安全性好。 

关键词: 肺炎支原体肺炎, 小儿咳喘灵口服液（浓缩型）, 临床疗效, 儿童

Abstract: Objective：To explore the clinical efficacy of Xiaoer Kechuanling oral solution (concentrated) in the treatment of children with Mycoplasma pneumoniae pneumonia and the changes in inflammatory factor levels.Methods：Totally 110 children with Mycoplasma pneumoniae pneumonia who received treatment in the Pediatric Department of Liaoning University of Traditional Chinese Medicine Affiliated Hospital were selected as the research subjects. Using a random number table method, they were divided into an observation group and a control group, with 55 cases in each group. All patients received basic western medicine treatment, and the observation group received combined treatment with Xiaoer Kechuanling oral solution (concentrated) additionally. Compare the clinical efficacy, symptom improvement time, time of pulmonary rales disappearing, levels of inflammatory factors, and incidence of adverse reactions during treatment between the two groups of children.Results：The total effective rate of the observation group(94.55%, 52/55) was higher than that of the control group(81.82%, 45/55)(P<0.05). The duration of fever, cough, expectoration, and pulmonary rales in the observation group was significantly shorter than that in the control group (P<0.05). There was no statistical difference in the improvement of the levels of tumor necrosis factor alpha(TNF-α) in these children between the two treatment regimens(P>0.05), while there was statistical difference in the improvement of IL-6 levels between the two treatment regimens (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment period (P>0.05).Conclusion：On the basis of western medicine treatment, the application of Xiaoer Kechuanling oral solution (concentrated) can effectively improve the clinical efficacy in the treatment of Mycoplasma pneumoniae pneumonia in children, shorten the duration of fever, cough, expectoration and lung rales and inhibit inflammatory reactions, and it is quite safe.

Key words: Mycoplasma pneumoniae pneumonia, Xiaoer Kechuanling oral solution(concentrated type), Clinical efficacy, Child